Current situation of direct oral anticoagulants in primary care in Spain: Positioning of SEMERGEN in 2023

被引:1
作者
Polo-Garcia, J. [1 ]
Pallares-Carratala, V. [2 ]
Turegano-Yedro, M. [1 ]
Romero-Vigara, J. C. [3 ]
Prieto-Diaz, M. A. [4 ]
Cinza-Sanjurjo, S. [5 ]
机构
[1] Ctr Salud Casar Caceres, Med Familiar & Comunitaria, Caceres, Spain
[2] Univ Jaime I, Dept Med, Med Familiar & Comunitaria, Castellon de La Plana, Spain
[3] Ctr Salud Alfajarin, Med Familiar & Comunitaria, Zaragoza, Spain
[4] Ctr Salud Vallobin La Florida, Med Familiar & Comunitaria, Oviedo, Spain
[5] Inst Invest Salud Santiago De Compostela IDIS, Ctr Salud Milladoiro, Ctr Invest Biomed Red Enfermedades Cardiovascu CIB, Med Familiar & Comunitaria,Area Salud Santiago Com, Santiago De Compostela, Spain
来源
MEDICINA DE FAMILIA-SEMERGEN | 2024年 / 50卷 / 03期
关键词
Vitamin K antagonists; Direct oral anticoagulants; Atrial fibrillation; NONVALVULAR ATRIAL-FIBRILLATION; PRIMARY-HEALTH-CARE; STROKE PREVENTION; RISK STRATIFICATION; COST-EFFECTIVENESS; CHA(2)DS(2)-VASC SCORE; ANTITHROMBOTIC THERAPY; ISCHEMIC-STROKE; WARFARIN; SAFETY;
D O I
10.1016/j.semerg.2023.102136
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Oral anticoagulation is the key to reduce the risk of stroke in atrial fibrillation. Although vitamin K antagonists (VKA) have classically been used for this purpose, they have been largely overcome by direct oral anticoagulants (DOAC), as demonstrated by evidence from clinical trials, real-life and population studies. In fact, all clinical practice guidelines recommend their use preferentially over VKA. However, in Spain the prescription of DOAC is subordinated to an inspection visa that includes the clinical conditions defined in the Therapeutic Positioning Report of the Spanish Medicines Agency, and that still imposes important restrictions on their use, limiting the benefits of using DOACs in patients with atrial fibrillation (AF), and also generating inequalities between the different autonomous communities. In fact, the use of DOAC in Spain is much lower than that observed in neighboring countries. This has made that while in other countries the incidence of ischemic stroke has decreased at the population level, along with a reduction in the cost per patient with AF, in Spain this decrease has been modest. For all these reasons, and for assuring the sustainability of the health care system, we ask for the elimination of the visa so that DOAC can be prescribed according to the recommendations made by the guidelines. In addition, we are also committed to reinforce medical education and decisions made by consensus with the patient, with the primary care physician acquiring a key role in the protection of the patient with AF.
引用
收藏
页数:18
相关论文
共 111 条
[71]   Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge [J].
Lippi, Giuseppe ;
Sanchis-Gomar, Fabian ;
Cervellin, Gianfranco .
INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (02) :217-221
[72]  
Llisterri Caro JL, 2019, Semergen, V45, P413
[73]  
Llisterri JL, 2017, Posicionamiento de SEMERGEN sobre la utilizacion de los anticoagulantes oralesde accion directa
[74]   The family doctor and the barriers to prescribing the new oral anticoagulants: Heterogeneity, inequality and confusion. Statement of the Spanish Primary Care and Family Medicine Societies [J].
Lobos Bejarano, Jose M. ;
Polo Garcia, Jose ;
Vargas Ortega, Diego .
ATENCION PRIMARIA, 2014, 46 (01) :1-3
[75]   Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis [J].
Ma, Fuxin ;
Xu, Wenlin ;
Chen, Jiana ;
Zhang, Jinhua .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (08) :1013-1022
[76]   Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people [J].
Maggioni, Aldo P. ;
Dondi, Letizia ;
Andreotti, Felicita ;
Pedrini, Antonella ;
Calabria, Silvia ;
Ronconi, Giulia ;
Piccinni, Carlo ;
Martini, Nello .
AMERICAN HEART JOURNAL, 2020, 220 :12-19
[77]   Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack [J].
Masjuan, Jaime ;
Alvarez-Sabin, Jose ;
Blanco, Miguel ;
de Felipe, Alicia ;
Gil-Nunez, Antonio ;
Gallego-Cullere, Jaime ;
Vivancos, Jose .
REVISTA DE NEUROLOGIA, 2014, 59 (01) :25-36
[78]   Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program [J].
Mazurek, Michal ;
Teutsch, Christine ;
Diener, Hans-Christoph ;
Dubner, Sergio J. ;
Halperin, Jonathan L. ;
Ma, Chang-Sheng ;
Rothman, Kenneth J. ;
Paquette, Miney ;
Zint, Kristina ;
Franca, Lionel Riou ;
Lu, Shihai ;
Bartels, Dorothee B. ;
Huisman, Menno V. ;
Lip, Gregory Y. H. .
AMERICAN HEART JOURNAL, 2019, 218 :123-127
[79]   Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program [J].
Mazurek, Michal ;
Huisman, Menno V. ;
Rothman, Kenneth J. ;
Paquette, Miney ;
Teutsch, Christine ;
Diener, Hans-Christoph ;
Dubner, Sergio J. ;
Halperin, Jonathan L. ;
Zint, Kristina ;
Franca, Lionel Riou ;
Lu, Shihai ;
Lip, Gregory Y. H. .
AMERICAN JOURNAL OF MEDICINE, 2018, 131 (08) :945-+
[80]   Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data [J].
Moret, Carla ;
Acosta-Isaac, Rene ;
Mojal, Sergi ;
Corrochano, Mariana ;
Jimenez, Blanca ;
Plaza, Melania ;
Souto, Juan Carlos .
PLOS ONE, 2023, 18 (02)